Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Cost of Revenue: 2019-2025

Historic Cost of Revenue for Burning Rock Biotech (BNR) over the last 7 years, with Sep 2025 value amounting to -$62.3 million.

  • Burning Rock Biotech's Cost of Revenue rose 17.19% to -$62.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.9 million, marking a year-over-year increase of 140.62%. This contributed to the annual value of $26.2 million for FY2024, which is 25.04% down from last year.
  • As of Q3 2025, Burning Rock Biotech's Cost of Revenue stood at -$62.3 million, which was down 184.56% from $73.7 million recorded in Q2 2025.
  • Burning Rock Biotech's 5-year Cost of Revenue high stood at $90.3 million for Q3 2022, and its period low was -$231.4 million during Q4 2022.
  • Moreover, its 3-year median value for Cost of Revenue was $40.9 million (2025), whereas its average is $5.3 million.
  • Examining YoY changes over the last 5 years, Burning Rock Biotech's Cost of Revenue showed a top increase of 656.01% in 2022 and a maximum decrease of 1,499.06% in 2022.
  • Over the past 5 years, Burning Rock Biotech's Cost of Revenue (Quarterly) stood at $16.5 million in 2021, then slumped by 1,499.06% to -$231.4 million in 2022, then rose by 29.55% to -$163.0 million in 2023, then spiked by 103.44% to $5.6 million in 2024, then grew by 17.19% to -$62.3 million in 2025.
  • Its Cost of Revenue stands at -$62.3 million for Q3 2025, versus $73.7 million for Q2 2025 and $40.9 million for Q1 2025.